Spasticity - Pipeline Review, Q4 2010

Global Markets Direct, December 2010, Pages: 42

Spasticity - Pipeline Review, Q4 2010

Summary

Global Markets Direct’s, “Spasticity Pipeline Review, Q4 2010”, provides an overview of the Spasticity therapeutic pipeline. This report provides information on the therapeutic development for Spasticity, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Spasticity. “Spasticity-Pipeline Review 2010, Q4 2010” is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team.

Scope

- A snapshot of the global therapeutic scenario for Spasticity.
- A review of the Spasticity products under development by companies and universities/research institutes based on information derived from company and industry-specific sources.
- Coverage of products based on various stages of development ranging from discovery till registration stages.
- A feature on pipeline projects on the basis of monotherapy and combined therapeutics.
- Coverage of the Spasticity pipeline on the basis of therapeutic class, route of administration and molecule type.
- Profiles of late-stage pipeline products featuring sections on product description, mechanism of action and research & development progress.
- Key discontinued pipeline projects.
- Latest news and deals relating to the products.

Reasons to buy

- Identify and understand important and diverse types of therapeutics under development for Spasticity.
- Identify emerging players with potentially strong product portfolio and design effective counter-strategies to gain competitive advantage.
- Plan mergers and acquisitions effectively by identifying players with the most promising pipeline.
- Devise corrective measures for pipeline projects by understanding Spasticity pipeline depth and focus of Spasticity therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline.

List of Tables
List of Figures
Introduction
Global Markets Direct Report Coverage
Spasticity Overview
Therapeutics Development
An Overview of Pipeline Products for Spasticity
Spasticity Therapeutics under Development by Companies
Spasticity Therapeutics under Investigation by Universities/Institutes
Late Stage Products
Comparative Analysis
Mid Clinical Stage Products
Comparative Analysis
Early Clinical Stage Products
Comparative Analysis
Pre-Clinical Stage Products
Comparative Analysis
Companies Involved in Spasticity Therapeutics Development
XenoPort, Inc.
IMPAX Laboratories, Inc.
GW Pharmaceuticals plc
Osmotica Pharmaceutical Corp.
Universities/Institutes Involved in Spasticity Therapeutics Development
Spasticity Therapeutics Assessment
Assessment by Monotherapy Products
Assessment by Route of Administration
Assessment by Molecule Type
Late Stage Drug Profiles – Companies
IPX056 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Sativex - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Late Stage Drug Profiles – Universities/Institutes
Baclofen - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Botulinum Toxin Type A - Drug Profile
Product Description
Mechanism of Action
R&D Progress
MEOPA - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Discontinued Products
Spasticity - Featured News
Sep 20, 2010: Merz Pharma Launches XEOMIN Patient Assistance Plan In Canada
Sep 13, 2010: XenoPort Announces Plans For Phase III Development Of Arbaclofen Placarbil For Spasticity
Sep 07, 2010: MERZ Pharma's XEOMIN Listed With Regular Benefit Status On AHWDBL
Aug 31, 2010: GW Pharmaceuticals And Bayer Receive Health Canada Approval For Sativex For Treatment Of Spasticity Due To Multiple Sclerosis
Jul 28, 2010: Almirall And GW Receive Regulatory Authorization For Sativex In Spain
Jun 21, 2010: GW Launches Sativex In UK To Treat Spasticity Associated With Multiple Sclerosis
Sep 08, 2009: XenoPort Reports Preliminary Results From A Safety And Tolerability Trial Of Arbaclofen Placarbil In Patients With Acute Back Spasms
Jun 30, 2009: XenoPort Reports Positive Results From A Phase 2 Trial Of Arbaclofen Placarbil In Spinal Cord Injury Patients With Spasticity
Apr 20, 2009: Impax Pharmaceuticals Reports Positive Achievements On Its Leading Brand Product Candidate IPX056
Dec 11, 2008: Impax Provides Update On Meeting With FDA To Review Phase III Trial Results For IPX056
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer

Customers who bought this item also bought

• Special Report: Market Opportunities in Symptomatic Treatments of Multiple Sclerosis
• Stakeholder Opinions: Spinal Cord Injury - Attractive niche market with multi-billion dollar potential
• Gastrointestinal Disorder Therapeutics to 2016 - High Unmet Needs Triggering Strong Growth in Crohn's Disease and Irritable Bowel Syndrome Markets
• Overactive Bladder (OAB) Therapeutics - Global Strategic Business Report
• Global Osteoporosis Therapeutics Market: Market Forecast, Patient Flow,Competitive Landscape, and Pipeline Analysis
• The Neurotechnology Industry 2012 Report
• Diabetes Diagnostics - Global Strategic Business Report
• Disinfectants - Global Strategic Business Report
• Handbook of Dystonia. Edition No. 2. Neurological Disease and Therapy
• Pipeline and Commercial Insight: Neuropathic Pain - Pipeline setbacks prolong Pfizer's supremacy